We are live on ! Find out more
DAWN

Day One Biopharmaceuticals
DAWN

Delisted

DAWN was delisted on the 22nd of April, 2026.

Back to rankings

130 hedge funds and large institutions have $952M invested in Day One Biopharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 56 increasing their positions, 35 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 35

5% more call options, than puts

Call options by funds: $813K | Put options by funds: $775K

1% more capital invested

Capital invested by funds: $941M → $952M (+$10.5M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

7% less funds holding

Funds holding: 140 → 130 (-10)

17.95% less ownership

Funds ownership: 107.12% → 89.17% (-18%)

41% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 22

Holders
130
Holders Change
-10
Holders Change %
-7.14%
% of All Funds
2.06%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
13
Increased
56
Reduced
35
Closed
22
Calls
$813K
Puts
$775K
Net Calls
+$38K
Net Calls Change
-$391K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$14.7M
2
PHS
PFM Health Sciences
California
+$14.1M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$5.39M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.8M
5
B
Braidwell
Connecticut
+$4.61M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$20M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$18.3M
3
Citadel Advisors
Citadel Advisors
Florida
-$9.98M
4
Goldman Sachs
Goldman Sachs
New York
-$9.74M
5
LGM
Logos Global Management
California
-$7.76M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$6.77M +$1.56M +119,262 +28%
Verition Fund Management
27
Verition Fund Management
Connecticut
$6.73M +$489K +37,491 +7%
Point72 Asset Management
28
Point72 Asset Management
Connecticut
$6.68M +$5.39M +413,560 +316%
SFM
29
Sphera Funds Management
Israel
$6.5M – – –
AG
30
Artal Group
Luxembourg
$6.13M – – –
DCM
31
Driehaus Capital Management
Illinois
$5.99M +$133K +10,212 +2%
PHP
32
Parkman Healthcare Partners
Connecticut
$5.72M +$497K +38,129 +9%
Marshall Wace
33
Marshall Wace
United Kingdom
$5.67M -$4.28M -327,797 -42%
Charles Schwab
34
Charles Schwab
California
$5.49M +$1.63M +125,050 +39%
N
35
Nuveen
North Carolina
$5.22M +$945K +72,443 +21%
Alyeska Investment Group
36
Alyeska Investment Group
Illinois
$4.79M – – –
Dimensional Fund Advisors
37
Dimensional Fund Advisors
Texas
$3.76M +$1.6M +123,007 +67%
CS
38
Candriam SCA
Luxembourg
$3.56M – – –
Walleye Capital
39
Walleye Capital
New York
$3.4M +$3.62M +277,206 New
WP
40
Woodline Partners
California
$3.34M +$803K +61,538 +29%
Rafferty Asset Management
41
Rafferty Asset Management
New York
$2.91M -$703K -53,924 -19%
ECM
42
ExodusPoint Capital Management
New York
$2.76M +$488K +37,424 +20%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$2.7M +$527K +40,387 +22%
Bank of America
44
Bank of America
North Carolina
$2.68M +$66.9K +5,129 +2%
SB
45
Samsara BioCapital
California
$2.41M – – –
D.E. Shaw & Co
46
D.E. Shaw & Co
New York
$2.41M -$224K -17,188 -8%
Deutsche Bank
47
Deutsche Bank
Germany
$2.17M +$120K +9,219 +5%
SAM
48
Simplify Asset Management
Nevada
$2.15M +$2.28M +175,018 New
Norges Bank
49
Norges Bank
Norway
$2.07M – – –
Morgan Stanley
50
Morgan Stanley
New York
$1.94M -$1.03M -79,258 -33%
1
2
3 4 5

DAWN Hedge Fund Activity: Q3 2023 in Review

130 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q3 2023, worth a combined $952M — up 1.1% from $941M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of DAWN and 13 opened new positions — a net loss of 9 holders — while 35 trimmed existing stakes and 56 added.

The largest buyer was BlackRock, adding an estimated $14.7M. The largest seller was Fidelity Investments, cutting an estimated $20M.

  • 130 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q3 2023, down from 140 in Q2 2023.
  • Funds reported $952M of Day One Biopharmaceuticals stock for Q3 2023, up 1.1% quarter-over-quarter.
  • 13 funds opened new Day One Biopharmaceuticals positions in Q3 2023 and 22 closed out, a net change of -9 holders.
  • The largest Day One Biopharmaceuticals buyer in Q3 2023 was BlackRock, an estimated $14.7M added.
  • The largest Day One Biopharmaceuticals seller in Q3 2023 was Fidelity Investments, an estimated $20M sold.

Based on aggregated 13F filings for Q3 2023.